Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era

被引:66
作者
Vittecoq, D
Escaut, L
Chironi, G
Teicher, E
Monsuez, JJ
Andrejak, M
Simon, A
机构
[1] Hop Paul Brousse, Serv Malad Infect & Med Interne, F-94804 Villejuif, France
[2] Hop Broussais, Serv Malad Cardiovasc, F-75674 Paris, France
[3] Agence Francaise Secur Sanit Prod Sante, Unite Pharmacovigilance, St Denis, France
关键词
side effects; hyperlipidemia; diabetes mellitus; acute myocardial infarction; atherosclerosis; HIV-1; statins;
D O I
10.1097/00002030-200304001-00010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To assess the incidence and the clinical features of coronary heart disease in HIV-infected patients. To assess atherosclerosis risk factors in this population. Methods: A review of our experience consisting of 16 patients with acute myocardial infarction (AMI) was the basis of our retrospective analysis of two cohorts in France. Incidence was compared with the national database on the incidence of AM] in the general population. Results: Incidence appears to be between 5 and 5.5 per 1000 person-years among HIV-infected patients. This accounts for at least a threefold increase in incidence (1.52 per 1000 person-years reported in the Monica database registry in France). Age of onset of AMI in HIV-infected patients (younger than 50 years in most cases) is a point of major concern and is an indirect way to confirm the increased incidence. AMI was typically of sudden onset without prior history of angina pectoris. Treatment and prognosis of AMI in this population has no specificity. Patients with coronary heart disease present several risk factors such as tobacco smoking, hypertension, diabetes mellitus and low high-density lipoprotein level. The links between AMI and protease inhibitor exposure is still a matter of debate, and longer duration of follow-up is needed in order to reach any conclusion. Conclusions: Coronary heart disease is of a higher than expected incidence in HIV-infected patients. The limitation of risk factors (mainly tobacco smoking) is a new challenge. An adaptation of the Framingham score is necessary to state the individual risk. Prospective, controlled studies are necessary to assess new strategies such as the role of statins and switching therapeutic regimens. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:S70 / S76
页数:7
相关论文
共 41 条
[1]   AN UPDATED CORONARY RISK PROFILE - A STATEMENT FOR HEALTH-PROFESSIONALS [J].
ANDERSON, KM ;
WILSON, PWF ;
ODELL, PM ;
KANNEL, WB .
CIRCULATION, 1991, 83 (01) :356-362
[2]  
ANDREJAK M, 2000, 8 ANN M EUR SOC PHAR
[3]   HIV-associated coronary arteritis in a patient with fatal myocardial infarction [J].
Barbaro, G ;
Barbarini, G ;
Pellicelli, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (23) :1799-1800
[4]  
Behrens G, 1998, LANCET, V351, P1958, DOI 10.1016/S0140-6736(98)26026-0
[5]   Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors [J].
Behrens, G ;
Dejam, A ;
Schmidt, H ;
Balks, HJ ;
Brabant, G ;
Körner, T ;
Stoll, M ;
Schmidt, RE .
AIDS, 1999, 13 (10) :F63-F70
[6]   Unique coronary arteriopathy associated with human immunodeficiency virus [J].
Best, PJM ;
Edwards, WD ;
Holmes, DR ;
Lerman, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) :272A-272A
[7]  
Cambou JP, 1997, ARCH MAL COEUR VAISS, V90, P1511
[8]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[9]  
CHALIFOUX LV, 1992, LAB INVEST, V67, P338
[10]  
CHEMINOT N, 2000, 7 C RETR OPP INF SAN